The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of Takeda’s Takhzyro (lanadelumab), aimed at treating hereditary ...

The results compare well with plasma kallikrein inhibitor Takhzyro (lanadelumab) in HAE, which is given by subcutaneous injection every two weeks, but can be reduced to once a month if patients ...

Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.